The European Medicines Agency is this week due to decide whether to back the approval of extended indications for a raft medicines that are already authorized in the EU. These include GW Pharmaceuticals’ Epidyolex, AstraZeneca’s Imfinzi and Eli Lilly’s Olumiant.
Requests by companies to broaden the therapeutic indication of around 20 products are listed as being up for an opinion on whether they should be approved at the latest monthly meeting of the EMA’s drug evaluation committee, the CHMP. The meeting is taking place from 20-23 July
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?